Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WOL071-007 in Atopic Dermatitis
NCT02576093Phase 1Completed
- Sponsor
- Dr. August Wolff
- Start
- Mar 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of WOL071-007 in atopic dermatitis (AD) (4 arms), sponsored by Dr. August Wolff. Primary endpoints: Safety of WOL071-007 at 7 days, Local tolerability at 7 days and 1 more. Started Mar 2014; status: completed.
02
Drugs
WOL071-007
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02576093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576093.